help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-0425
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
93/4/1276    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Shaw, L. J.
Right arrow Articles by Pepine, C. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaw, L. J.
Right arrow Articles by Pepine, C. J.
Related Collections
Right arrow Cardiovascular Endocrinology
Right arrow Female Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 93, No. 4 1276-1284
Copyright © 2008 by The Endocrine Society

Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation

Leslee J. Shaw, C. Noel Bairey Merz, Ricardo Azziz, Frank Z. Stanczyk, George Sopko, Glenn D. Braunstein, Sheryl F. Kelsey, Kevin E. Kip, Rhonda M. Cooper-DeHoff, B. Delia Johnson, Viola Vaccarino, Steven E. Reis, Vera Bittner, T. Keta Hodgson, William Rogers and Carl J. Pepine

Division of Cardiology, Department of Medicine (L.J.S., C.N.B.M.), Cedars-Sinai Research Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology (R.A.), Cedars-Sinai Medical Center, Los Angeles, California 90048; University of Southern California (F.Z.S.), Los Angeles, California 90089; National Heart, Lung, and Blood Institute (G.S.), NIH, Bethesda, Maryland 20814; Department of Medicine (G.D.B., T.K.H.), Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Epidemiology (S.F.K., K.E.K., B.D.J.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213; Division of Cardiology (R.M.C.-D., C.J.P.), Department of Medicine, University of Florida, Gainesville, Florida 32611; Division of Cardiology (V.V.), Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30322; Cardiovascular Institute (S.E.R.), University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213; and Division of Cardiovascular Disease (V.B., W.R.), Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294

Address all correspondence and requests for reprints to: Leslee J. Shaw, Ph.D., c/o WISE Coordinating Center, University of Pittsburgh, 127 Parran Hall, Graduate School of Public Health, 130 DeSoto Street, Pittsburgh, Pennsylvania 15261. E-mail: lshaw3{at}emory.edu.

Background: Women with polycystic ovary syndrome (PCOS) have a greater clustering of cardiac risk factors. However, the link between PCOS and cardiovascular (CV) disease is incompletely described.

Objective: The aim of this analysis was to evaluate the risk of CV events in 390 postmenopausal women enrolled in the National Institutes of Health–National Heart, Lung, and Blood Institute (NIH-NHLBI) sponsored Women’s Ischemia Syndrome Evaluation (WISE) study according to clinical features of PCOS.

Methods: A total of 104 women had clinical features of PCOS defined by a premenopausal history of irregular menses and current biochemical evidence of hyperandrogenemia. Hyperandrogenemia was defined as the top quartile of androstenedione (≥701 pg/ml), testosterone (≥30.9 ng/dl), or free testosterone (≥4.5 pg/ml). Cox proportional hazard model was fit to estimate CV death or myocardial infarction (n = 55).

Results: Women with clinical features of PCOS were more often diabetic (P < 0.0001), obese (P = 0.005), had the metabolic syndrome (P < 0.0001), and had more angiographic coronary artery disease (CAD) (P = 0.04) compared to women without clinical features of PCOS. Cumulative 5-yr CV event-free survival was 78.9% for women with clinical features of PCOS (n = 104) vs. 88.7% for women without clinical features of PCOS (n = 286) (P = 0.006). PCOS remained a significant predictor (P < 0.01) in prognostic models including diabetes, waist circumference, hypertension, and angiographic CAD as covariates.

Conclusion: Among postmenopausal women evaluated for suspected ischemia, clinical features of PCOS are associated with more angiographic CAD and worsening CV event-free survival. Identification of postmenopausal women with clinical features of PCOS may provide an opportunity for risk factor intervention for the prevention of CAD and CV events.




This article has been cited by other articles:


Home page
PhysiologyHome page
C. Baylis
Sexual Dimorphism of the Aging Kidney: Role of Nitric Oxide Deficiency
Physiology, June 1, 2008; 23(3): 142 - 150.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. S. Guzick
Do Cardiovascular Risk Factors in Polycystic Ovarian Syndrome Result in More Cardiovascular Events?
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1170 - 1171.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society